Educational Activities Archives

This module reviews features of skin and soft tissue infections among people who inject drugs, reviews risk factors for Hepatitis C (HCV) and HIV, describes prevention interventions for HCV and HIV, and discusses treatment approaches for HCV and HIV in patients with opioid use disorder.

Co-occurring psychiatric conditions are frequently seen in patients with substance use disorders. Clinicians should be alert to the signs and symptoms of common psychiatric disorders and should understand how to distinguish independent psychiatric disorders from substance-induced disorders. Depressive disorders and anxiety disorders, including post-traumatic stress disorder, are the most common co-occurring conditions, though ADHD is often encountered across the range of substance use disorders. Substance use disorder patients with co-occurring psychiatric disorders will respond to most standard psychological and pharmacological treatments for these psychiatric conditions, though clinicians should avoid the use of scheduled medications and must always focus on sobriety as a primary treatment goal. Treatment that integrates addiction and psychiatric care is the most effective.

Brain development during adolescence makes youth particularly vulnerable to both initiating substance use and developing substance use disorders (SUD). Alcohol and cannabis use are both common and the impacts of these substances on the developing brain leads to a predictable set of consequences. Primary and secondary prevention and treatment can all improve outcomes. This module discusses Screening, Brief Intervention, and Referral to Treatment (SBIRT) to identify and address substance use, and the medical management of SUD treatment in primary care.

Substance Use disorders in Older Adults is a growing problem not only in the United States but throughout the developed world. The Baby Boomer generation, born between 1946 and 1964 is turning 58-76 years old this year. This group is presenting with more Substance Use Disorders and need for substance use treatment now. The use of an artificial cut off age of 65 years of age as the definition of elderly or old is somewhat arbitrary and this will be discussed. The module will look at the prevalence, screening and treatment of tobacco, alcohol, opioids, non-medical use of prescription drugs and illicit opioids as well as stimulants and cocaine, marijuana and non-opioid sedative hypnotic agents. A case vignette will drive the CME portion and elucidate the tenants of the module.

This presentation explores how pharmacists and social workers can work together to expand access to medications for opioid use disorder by transforming interprofessional collaboration and creating hubs of care.

Explore the Stages of Change Model and its usefulness in identifying and overcoming barriers to optimal access for opioid use disorder (OUD) services. Attendees will hear from a leading expert with over 25 years of experience in the health and wellness field.